Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Merus N.V. (MRUS : NSDQ)

• Company Description    Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands. Number of Employees: 260

• Price / Volume Information    Yesterday's Closing Price: $69.58 Daily Weekly Monthly 20 Day Moving Average: 529,666 shares Shares Outstanding: 75.63 (millions) Market Capitalization: $5,262.61 (millions) Beta: 1.19 52 Week High: $70.65 52 Week Low: $33.19 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.94% 2.12% 12 Week 32.31% 20.18% Year To Date 65.47% 48.21%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL UPPSALALAAN 17 - UTRECHT,P7 3584 CT NLD ph: 31-85-016-2500 fax: - s.spear@merus.nl http://www.merus.nl

• General Corporate Information    Officers Sven (Bill) Ante Lundberg - President; Chief Executive Officer; Principal Exec Anand Mehra - Chairman of the Board of Directors Gregory D. Perry - Chief Financial Officer; Principal Financial Offic Harry Shuman - Chief Accounting Officer; Principal Accounting Off Len Kanavy - Director Peer Information Merus N.V. (CORR.) Merus N.V. (RSPI) Merus N.V. (CGXP) Merus N.V. (BGEN) Merus N.V. (GTBP) Merus N.V. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: N5749R100 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 10/30/25 Share - Related Items Shares Outstanding: 75.63 Most Recent Split Date: (:1) Beta: 1.19 Market Capitalization: $5,262.61 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.20 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-5.67 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 10/30/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 6.25 Price/Cash Flow: - Price / Sales: 93.59 EPS Growth vs. Year Ago Period: -175.31% vs. Previous Quarter: -59.29% Sales Growth vs. Year Ago Period: 20.40% vs. Previous Quarter: -66.67% ROE 06/30/25 - -50.28 03/31/25 - -35.99 12/31/24 - -29.48 ROA 06/30/25 - -42.00 03/31/25 - -29.83 12/31/24 - -23.91 Current Ratio 06/30/25 - 8.39 03/31/25 - 5.86 12/31/24 - 6.54 Quick Ratio 06/30/25 - 8.39 03/31/25 - 5.86 12/31/24 - 6.54 Operating Margin 06/30/25 - -623.48 03/31/25 - -442.87 12/31/24 - -499.20 Net Margin 06/30/25 - -685.64 03/31/25 - -506.73 12/31/24 - -595.93 Pre-Tax Margin 06/30/25 - -670.59 03/31/25 - -490.45 12/31/24 - -573.37 Book Value 06/30/25 - 11.13 03/31/25 - 8.62 12/31/24 - 9.46 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©